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ABSTRACT 
In 1981， de Bold and colleagues demonstrated an increase in the 
excretion of sodium and water following injection of a cardiac atrial 
extract into rats (de Bold et al. 1981) . A few years later, the 
structure of an unique cardiac peptide, atrial natriuretic peptide 
(ANP), was identified. Acute administration of synthetic ANP has been 
shown to lower blood pressure in conscious laboratory animals (Allen 
et al. 1987) and man (Richards et al. 1985a) . Although a specific 
receptor for ANP has been found in the rat's heart and other peripheral 
tissues (Bianchi et al. 1985), the mechanism of this acute hypotensive 
effect is still controversial. The aim of present work was to 
investigate this problem by studying the effect of ANP on heart muscle 
using perfused guinea-pig and rat left atrium preparations, and on IN 
SITU mesenteric artery preparation of rats. 
In isolated atrial preparations, ANPCIO'^^M - and Krebs 
solution with different concentrations of calcium ion were perfused 
into the left atrial cavity. The atrial end-diastolic pressure, the 
atrial peak pressure and pulse pressure which the atrium developed 
actively were measured. Though the atrial preparations showed the 
normal inotropic responses to the changes of calcium concentration, 
ANP had no significant effect on atrial pulse pressure. 
In mesenteric artery preparations, medium size (resting diameter 
from 250 to 325 micrometer) arteries were exposed under a dissection 
microscope and the fat along the arteries was cut away carefully. After 
dissection, the preparations were moved to a video microscope system 
and the diameters of the arteries were measured. After equilibration, 
the arteries were preconstricted by noradrenaline. Then normal Ringer's 
solution, ANP(10"^M) and sodium nitroprusside (10"^M) were superfused to 
the arteries. The results showed that ANP caused a slight but 
significant relaxation (15%) of the vessels. With sodium nitroprusside 
the relaxation was almost 100%. 
The results suggest that dilatation of peripheral blood vessels 
contributes more than depression of cardiac contractility to the fall 
in blood pressure with ANP. 
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1.1 Historical Perspectives 
Kisch (1956) first described the presence of granules 
in the atrial cardiocytes of guinea-pig. He pointed out a 
morphological difference between atrial and ventricular 
cardiocytes in the heart of the guinea-pig. He observed, as 
others did subsequently, that atrial cardiocytes in mammals 
unlike ventricular cardiocytes, have morphological features 
of secretory cells. The most obvious expression of this 
differentiation is the presence of membrane-bound storage 
granules - the specific atrial granules - which, after 
conventional processing for electron microscopy, display an 
electron 一 dense core. The granules range in diameter from 
250 to 500 nanometres. They locate in one and occasionally 
in both poles of the nucleus and adjacent to golgi complex. 
Several years later, Jamieson and Palade (1964) 
demonstrated that such granules were present in cardiocytes 
of the atria of all mammalian species studied (bats, 
hamsters, guinea—pigs, mice, rats, rabbits, dogs, pigs, and 
humans) and observed that they were present exclusively in 
the atria and not in the ventricles. On the other hand, 
Bencosme and Berger (1971) reported that the granules were 
also present in the ventricular cardiocytes of many non-
mammalian vertebrates, such as amphibians, reptiles, and 
birds. 
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The atrial granules are primarily polypeptide-storing 
particles. No carbohydrate, lipid or other chemical species 
can be detected within the granules. Histochemically atrial 
granules display properties in common with polypeptide 
hormone-containing granules (de Bold et al. 1978). On the 
other hand, changes in water and electrolyte balance 
significantly alter the specific atrial granules population 
in the rat (de Bold 1979) . These observations led to the 
hypothesis that the specific atrial granules store a 
polypeptide that is involved in the regulation of water and 
electrolyte balance. The experimental testing of this 
hypothesis led to the finding that atrial extract elicits 
a natriuretic effect in rat (de Bold et al. 1981). In the 
same experiment, it was also found that the blood pressure 
decreased after intravenous injection of the atrial 
extract. 
Many experiments have been done to find an explanation 
of this hypotensive effect. Evidence has been found that 
the atrial extract has an effect on vascular smooth muscle. 
Atrial extract has been shown to possess a vasorelaxant 
effect on preconstricted vascular smooth muscle (Deth et 
al. 1982 ； Currie et al. 1983 ) and this effect is not 
dependent on the presence of endothelial cells (Scivoletto 
and Carvalho 1984). Nevertheless, Ackermann et al • (1984) 
reported that the injection of atrial extract into 
anaesthetized rats produced a fall in mean arterial blood 
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pressure which was mainly due to a depressed cardiac 
output. When the animals were vagotomized, the hypotensive 
effect was less marked, but was entirely due to a reduction 
in total peripheral resistance. This reduction was greater 
when the carotid sinus was denervated. This suggests that 
the hypotensive effect of ANP in the rat is the result of 
failure to increase cardiac output in compensation for 
peripheral vasodilation, and that reflex mechanisms play an 
important role in this hypotensive effect. It also suggests 
a cardioinhibitory effect in addition to the peripheral 
vascular effect. Furthermore, Pegram et al. (1985) reported 
that atrial natriuretic extract administered intravenously 
to conscious Wistar-Kyoto (WKY) and spontaneously 
hypertensive (SHR) rats produced an immediate decrease in 
mean arterial pressure that reached maximum within 5 minute 
in both strains. Cardiac output decreased approximately 14% 
following administration of atrial extract. Organ blood 
flow was significantly decreased in skin, brain, heart, 
kidneys, and splanchnic organs of WKY and in skin, muscle, 
heart, and splanchnic organs of SHR following 
administration of atrial extract. These data indicate that 
atrial natriuretic extract has an effect on systemic and 
regional hemodynamics in conscious rats that differs 
markedly from those of vasodilators such as nitroglycerin 
or hydralazine. Moreover, Atrial extract also reduces the 
aldosterone release from rat zona glomerulosa cells 
(Atarashi et al. 1984). 
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The results of all these experiments with atrial 
extract indicate that atrial factor may take part in the 
regulation of fluid volume and blood pressure. It may have 
therapeutic uses in water and electrolyte imbalance and in 
some, cardiovascular disorders. Therefore, much work has 
been done to clarify the structure of this atrial factor 
and to manufacture it synthetically. 
4 
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1.2 Natures of AKP 
1.2.1 Structure of ANP: 
With the lightning pace of modern biomedical research, 
it took just two years to describe the structure of unique 
cardiac peptide and to product synthetic forms of it. The 
major intracellular form of ANP is the propeptide of 126 
amino acids (Nakao et al • 1984 ； Vuolteenaho et al • 1985; 
Morii e亡 al• 1986). In a more detailed study, Thibault et 
al. (1987) isolated atrial granules and purified their ANP 
content. They clearly demonstrated that the intragranular 
form is only pro-ANP (Asn-1 to Tyr-12 6) , as shown in the 
upper panel of Fig.1. 
Examination of ANP in the plasma by gel filtration or 
high performance liquid chromatography (HPLC) (Sugiyama et 
al• 1984; Sugawara et al • 1985) showed that it circulates 
in a low molecular weight form. Then plasma ANP was 
purified and its sequence was determined directly as the 
28-residue peptide (Ser-99 to Tyr-12 6) (Thibault et al. 
1985) • The amino acid sequence of plasma ANP is almost 
identical throughout mammalian species except the position 
110 which is isoleucine in mouse (Seidman et al • 1984), rat 
(Flynn et al• 1983), and rabbit (Oikawa et al. 1985) ANP, 
whereas human (Kangawa and Matsuo 1984; Seidman et al. 
1984), ox (Ong et al. 1986), and dog (Oikawa et al. 1985) 
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ANP have methionine in this position, as shown in the lower 
panel of Fig. 1. Moreover, other atrial peptides have also 
been isolated from rat plasma such as atriopeptin 工（Ser-
103 to Ser-123), atriopeptin II (Ser-103 to Arg-125) and 
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1-2.2 Tissue Distribution of ANP: 
Following the discovery of ANP bioactivity (de Bold e亡 
al* 1981), it was generally thought that ANP synthesis was 
exclusive to atria. This belief was reinforced by previous 
findings of secretory like granules present in atria but 
not in ventricles (Jamieson and Palade 1964), and in early 
bioassays ventricular extracts were used as negative 
controls (de Bold et al • 1981) . With the development of 
specific immunocytochemical assays and radioimmunoassays 
(RIAs), and the availability of cDNA probes, it becomes 
possible to assess the distribution of ANP iriRNA and 
peptides in extra-atrial tissue. The ANP gene now appears 
to be expressed in number of tissues including heart 
ventricles, lungs, aortic arch, anterior pituitary gland 
and various brain regions. in addition, ANP 
immunoreactivity has been detected in a number of other 
tissues in man and in various animal species. 
As well as RNA from atria, RNA prepared from rat 
ventricles also contains a weak hybridizing band which 
comigrates with the atrial transcripts. This suggests that 
the ANP gene is also expressed in ventricles, albeit to a 
much lesser extent (Zivin et al. 1984). With the aid of a 
32p-labelled ANP cDNA probe in In situ hybridization 
experiments, specific labelling was observed in both atrial 
and ventricular cardiocytes, confirming the presence of ANP 
8 
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transcripts in heart ventricles (Nemer et al. 1986). 
Moreover, the molecular weight distribution of ventricular 
ANP is identical to that of atrial peptide, as was revealed 
by HPLC analysis. However, ventricular ANP content is 1000-
fold lower than atrial ANP content (Nemer et al. 1986). 
Thus, it appears that the ANP gene is expressed in all 
heart compartments and that ANP is a cardiac and not an 
exclusively atrial hormone, as was originally thought. 
Furthermore, the finding of both high and low 
molecular weight forms of iimunoreactive ANP (irANP) in the 
rat hypothalamus was the first demonstration of the 
extracardiac presence of ANP (Tanaka et al. 1984). Then 
Jacobowitz et al • (1985) discovered ANP-containing nerve 
fibers and cell bodies in the preoptic-hypothalamic area, 
amygdala, mesencephalon, and pons. This same group 
undertook a detailed iimtiunohistochemical mapping of ANP in 
the rat brain and spinal cord (Skofitsch et al • 1985) . ANP-
like imimnoreactivity was evident throughout the rat 
nervous system. Relatively high density of irANP was 
observed in the anteroventral third ventricular area, a 
region associated with blood pressure regulation and volume 
homeostasis (Hartle and Brody 1984). These observations 
suggest that ANP may be involved in the central regulation 
of blood pressure and fluid balance. Moreover, its presence 
in the nucleus periventricularis suggests that ANP may 
modulate cardiovascular centers. On the other hand, the 
9 
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possible role of ANP as a neurotransmitter and 
neuroregulator was suggested by finding irANP in the 
peripheral autonomic nervous system. A biologically active 
ANP-like peptide was demonstrated in rat ganglia nodosa 
(Debinski et al. 1986) and in superior cervical ganglia 
(Gutkowska et al. 1987). 
The kidney is a major target organ for ANP (Sakamoto 
et al. 1985 ； McKenzie et al • 1985), and not surprisingly 
irANP has been detected in various parts of the kidney. 
Most of the irANP determined by RIA has been found in the 
r e n a l c o r t e x . N e v e r t h e l e s s , t h e d e t a i l e d 
immunocyctochemical studies made by McKenzie et al. (1985) 
have revealed intense intracellular staining in the 
cortical and medullary collecting tubules and ducts, not 
only in rat but also in horse, pig, monkey, and human 
kidneys. The localization of ANP in different renal tissues 
may have important implications for its proposed action 
sites. 
In the aorta, irANP has been localized to the 
adventitia of the arch in regions thought to contain the 
aortic baroreceptors (Gardner et al• 1987). This suggests 
a role for ANP in blood pressure regulation through the 
baroreceptor reflex. In addition, ANP immunoreactivity has 
also been detected in adrenal medullary chromaffin cells 
(McKenzie et al• 1985), submaxillary gland (Cantin et al• 
10 
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1984c) and in the thyroid gland (Matsuo et al. 1985). The 
finding of ANP in different tissues suggests that this 
cardiac hormone ends up in a number of target organs, 
possibly to regulate blood pressure and fluid balance. 
1.2.3 Plasma Concentration of ANP: 
Basal irANP plasma concentration in the rat range from 
26 to 33 pmol/l (Eskay et al. 1986). The range in healthy 
man is from 2.2 pmol/l to 22 pmol/l (Gutkowska et al. 
1985)• The plasma level of ANP is similar to that of other 
peptide hormones such as vasopressin. Furthermore, the 
plasma concentration is two-fold higher in right atrium as 
compared to venous blood (Burgisser et al • 1985). It 
indicates that the right atrium is the site of release of 
ANP into circulation. 
Increased plasma concentrations of irANP are noted in 
states of volume overload such as heart failure (Tikkanen 
et al. 1985), chronic renal failure (Rascher et al• 1985), 
and primary aldosteronism (Tunny et al • 1986). Essential 
hypertensive patients are said to have elevated plasma 
concentrations of irANP (Sugawara et al. 1985; Sagnella et 
a2. 1986), although overlap with nonnotensive subjects is 
considerable. In animal model, plasma ANP of spontaneously 
hypertensive rat (SHR) is increased with age and blood 
pressure (Morii et al• 1986). The plasma ANP level of Dahl 
11 
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salt-sensitive rats is markedly elevated with the 
development of hypertension on a high-salt diet (Tanaka et 
al. 1986). 
12 
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1.3 Release of AKP 
The diuresis and natriuresis resulting from left 
atrial distension are attributed to stretch receptors in 
the left atrium which would be responsible for a 
homeostatic mechanism linking changes in circulatory volume 
with renal responses (Henry et al. 1956). It has also been 
suggested that the diuresis induced by the distension of 
the left atrium is probably due to a diuretic factor of 
unknown origin (Linden 1979). The discovery of ANP in 
specific atrial granules (de Bold 1982) has provided new 
perspectives in our understanding of the mechanisms 
controlling diuresis and natriuresis induced by increased 
in the atrial pressure. The first indirect evidence that 
ANP can be released by the atria came from Dietz (1984). 
Using an isolated rat heart-lung preparation, Dietz 
demonstrated the presence of a natriuretic substance in the 
perfusate fluid, arising in response to increase in right 
atrial pressure. This finding was confirmed by a specific 
ANP RIA. It was further demonstrated that the peptide can 
be released not only by an isolated preparation but also 
into the circulation in vivo following saline volume 
expansion (Cantin et al• 1984a; Lang et al. 1985). 
The best documented and probably most important 
stimulus of ANP release is atrial stretch. In vitro 
demonstration that atrial distension releases ANP was made 
13 
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by Dietz (1984) who elevated central venous pressure in the 
denervated rat heart-lung preparation causing release of 
ANP as estimated by bioassay. Ruskoaho et al• (1986) also 
demonstrated that the release of ANP is through direct 
stretch of the atrial wall when they found a rise in 
immunoreactive ANP in the perfusate collected from the 
isolated perfused Langendorff heart preparation as the 
right atrial pressure was raised by 1-5 iimiHg; this 
preparation has no extrinsic neural connections. Moreover, 
Schiebinger and Linden (1986) examined the influence of 
resting tension on immunoreactive ANP secretion by isolated 
superfused rat atria. In non-paced and paced atria, 
increasing resting tension three to five-fold" caused 
immunoreactive atrial natriuretic peptide secretion to 
increase by 35 ± 5绘 and 30 士 3% respectively. To exclude 
the possibility that release of norepinephrine or 
acetylcholine from endogenous nerve endings was mediating 
this effect, the atria were superfused with the combination 
of propranolol, phentolamine and atropine. The antagonists 
did not block the rise in immunoreactive atrial natriuretic 
peptide secretion induced by increasing the resting 
tension. The results suggest that the influence of resting 
tension on immunoreactive atrial natriuretic peptide 
excretion results from direct mechanical stretch and is not 
mediated by release of endogenous neurotransmitters. 
Data from animal experiments and from in vitro studies 
14 
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leave no doubt that atrial stretch is a potent regulator of 
ANP release. Evidence in man also supports the primacy of 
atrial stretch. For example, saline infusion (Tunny et al. 
1986) and exercise (Bollerslev et al • 1987) all of which 
increase atrial pressure (and therefore atrial stretch), 
are associated with a rise in plasma ANP in normal man. 
Further, close relationships between atrial (or pulmonary 
artery wedge) pressure and ANP levels have been observed in 
man especially in cardiac failure (Bates et al • 1986; 
Richards et al. 1986 )• It now seems clear enough that any 
manoeuvre conducive to a direct stretch of the atrial wall 
stimulates ANP release; however, it is not yet known which 
internal signal responds to this stretch. 
Besides the stretch of atrial wall, other factors may 
play a role in the release of ANP including some hormonal 
factors and nervous control. Intravenous administration of 
vasopressin to anaesthetized dogs elicits a obvious 
increase in plasma ANP which is significantly different 
from infusion of normal saline only (Inoue et al. 1988). 
Moreover, norepinephrine produces a biphasic rise in ANP 
secretion by both a- and 6-adrenergic mechanisms from 
isolated rat atria (Schiebinger et al. 1987). In addition, 
Methacholine inhibits norepinephrine—stimulated ANP 
secretion. This suggests that activation of the sympathetic 
nervous system may enhance ANP secretion, whereas a rise in 
parasympathetic tone may lower ANP secretion. In the 
15 
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central nervous system, Itoh et al. (1988) examined the 
effects of intracerebroventricular administration of 
angiotensin 工工 on the plasma ANP level in conscious 
unrestrained rats. Administration of angiotensin 工工 
significantly enhanced ANP secretion induced by volume 
loading with infusion of saline. Central angiotensin 工工一 
induced ANP secretion was significantly attenuated by 
pretreatment with intravenous administration of the VI-
r e c e p t o r a n t a g o n i s t o f v a s o p r e s s i n o r 
intracerebroventricular administration of phentolamine. 
These results indicate that the brain renin-angiotensin 
system modulates ANP secretion in response to volume 
loading through the stimulation of vasopressin secretion or 
the activation of the central a-adrenergic neural pathway. 
Therefore, the control mechanisms of ANP release are 
complicated and need further clarification. 
16 
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1.4 Biological Effects of ANP 
1.4.1 Cardiovascular Effects of ANP: 
de Bold et al. (1981) first reported that atrial 
extract caused hypotension in addition to diuresis and 
natriuresis. This hypotensive effect was confirmed by acute 
administration of synthetic ANP in anaesthetized and 
conscious experimental animals (Maack and Kleinert 1986; 
Criscione e亡 al • 1987; Allen et al • 1987) and in man 
(Richards et al. 1985a). Although synthetic ANP has been 
administered to humans, the haemodynamic mechanisms by 
which ANP reduces blood pressure are still controversial. 
Ackermann et al. (1984) reported that intravenous injection 
of the atrial extract into anaesthetized rats produced a 
fall in mean arterial blood pressure which was mainly due 
to a depressed cardiac output. When the animals were 
vagotomized the hypotensive effect was less marked, but was 
entirely due to a reduction in total peripheral resistance. 
This reduction was greater when the carotid sinus was 
denervated. This suggests that the hypotensive effect of 
ANP in the rat results from failure to increase cardiac 
output in compensation for peripheral vasodilation, and in 
which reflex mechanisms play an important role. These 
results were later confirmed in the dog using a synthetic 
peptide (Koyama et al. 1986). Furthermore, using conscious 
rats chronically instrumented with electromagnetic flow 
17 
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probes, a decrease in cardiac output and increase in 
vascular peripheral resistance after administration of 
synthetic ANP have been reported (Lappe et al• 1985). The 
increase in peripheral resistance has been ascribed to 
reflex compensatory mechanisms. Similar results have been 
reported in conscious sheep, where a decreased cardiac 
output accompanied by a rise in total peripheral resistance 
have been described following a short period infusion of 
atriopeptin 工工（Breuhaus et al. 1985). However, total 
peripheral resistance decreases slightly in sympathetomized 
rats after ANP administration but it is unchanged in intact 
animals (Sasaki et al. 1986). These effects on blood 
pressure and cardiac output seem not to be mediated by a 
direct negative inotropic effect of ANP on cardiac muscle 
because cardiac filling pressure decreases (not increases) 
(Lappe et al• 1985; Breuhaus et al• 1985 )• Also, cardiac 
pumping ability in isolated perfused hearts (Otero et al• 
1987) and in anaesthetized rats (Natsume et al • 1986) is 
unaltered by ANP. Similarly, ANP does not alter cardiac 
rhythm through a direct effect on the sinoatrial node 
(Natsume et al • 1986)• Thus, the primary means by which ANP 
diminishes cardiac output is likely through its action in 
the peripheral circulation to decrease venous return. On 
the other hand, ANP relaxes precontracted conduit vessels 
(Winquist et al. 1984b), and thus many investigators assume 
that dilation of resistance-sized arteries mediates the 
hypotensive response. However, resistance vessels from the 
18 
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brain and mesenteric territory appear in vitro to be more 
resistant than the renal vascular bed to the relaxant 
effect of ANP (Aalkjaer et al• 1985; Osol et al. 1986). 
ANP also acts on a variety of models of experimental 
hypertension. Acute administration of synthetic ANP has 
been shown to have a profound and prolonged hypotensive 
effect in anaesthetized (Garcia et al• 1985) or conscious 
(Pegram et al. 1985; Seymour et al. 1987) 2K-1C and IK-IC 
hypertensive rats. But the studies of the effects of ANP 
on spontaneously hypertensive rats (SHR) have yielded 
contradictory results. The fall in blood pressure“ on SHR 
has been reported to be greater than (Pang et al • 1985; 
Kondo et al. 1986) or equal to (Kihara et al. 1985) that in 
normotensive Wistar-Kyoto (WKY) rats. The mechanism 
involved in the hypotensive and antihypertensive effects of 
ANP remains, however, to be further investigated. 
At this time, it is necessary to emphasize the fact 
that all these experiments have been performed under acute 
administration of ANP. The chronic administration of ANP 
lasting for several days may have completely different 
effects on blood pressure and natriuresis than those seen 
after acute administration. Chronic infusion of ANP for up 
to 12 days reduces blood pressure in models of experimental 
hypertension, without having any blood pressure lowering 
effect in the normotensive controls. As discussed 
19 
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previously, a reduction in cardiac output and/or vascular 
peripheral resistance may be the acute effect of ANP, but 
the mechanisms involved in its chronic hypotensive effect 
are still not clear. 
1.4.2 Renal Effects of ANP: 
The most consistent effects of ANP are diuresis and 
natriuresis. Atrial extracts of various mammals such as 
cattle, pig, dog, hamster, mouse, rat, monkey and man 
possess diuretic and natriuretic activity (de Bold et al. 
1981; Trippodo et al. 1983； Forssmann et al. 1983； de Bold 
and Salerno 1983； Nemeh and Gimore 1983； Chimoskey et al. 
1984). The observation of the rapid onset (within 1-2 min.) 
and short duration (less than 2 0 min.) of the renal effects 
has been confirmed by all subsequent studies. The 
intravenous (i.v.) injection of an atrial extract to rats 
not only produces diuresis and natriuresis but also 
increases renal excretion of potassium, calcium, magnesium, 
and phosphate (Keeler and Azzarolo 1983). These 
observations have been confirmed by direct injection into 
the dog renal artery of synthetic ANP (Arg-101 to Tyr-126) 
(Seymour et al. 1985). Sustained (5 days) infusion of ANP 
in the dog, however produces only a transient increase in 
glomerular filtration rate (GFR) (Granger et al• 1986). 
Radioautographic studies have now shown that most of 
the ANP binding sites in the kidney are localized in 
20 
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glomeruli (Bianchi et al. 1986c). They are also present, to 
a lesser degree, in the outer medullary descending vasa 
recta and inner medullary collecting duct cells (Bianchi et 
al • 1987) . Moreover, they are also present on the 
endothelium and smooth muscle cells of all renal vessels 
(Bianchi et al • 1985). At the electron microscope level, 
the binding sites in glomeruli are selectively localized on 
the podocytes of visceral epithelial cells (Bianchi et al. 
1986)• This also seems to be the case in humans, where the 
exposure of cultured glomerular visceral epithelial cells 
to ANP leads to more cGMP formation than in the case of 
mesangial cells (Ardaillou et al. 1986). 
Physiologically, ANP acts directly on the kidney to 
increase the glomerular filtration rate (GFR) (Atlas et al. 
1984,• Huang et al• 1985). In regard to the renal 
vasculature, while ANP dilates arcuate and interlobular 
arteries and afferent arterioles, it constricts efferent 
arterioles. This leads to an increase in glomerular 
capillary hydrostatic pressure, which in turn explains, at 
least in part, the increase in GFR (Maack and Kleinert 
19867 Schnermann et al. 1986). As we have seen above, ANP 
has a direct effect on glomerular cells: binding sites are 
localized on the podocytes of visceral epithelial cells, 
which probably indicates that the stimulation of cGMP by 
ANP is due to the activation of particulate guanylate 
cyclase which is located on the surface of these cells. 
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These results strongly suggest the one of the main effects 
of ANP is to increase the ultrafiltration coefficient 
(Fried et al • 1986) by dilating the afferent arterioles, 
constricting the efferent arterioles, and modulation the 
size of 丨 p o r e s 丨 and the shape of foot processes. In 
addition to its vascular and haemodynamic effects, ANP acts 
directly or indirectly to inhibit the load-reabsorption 
balance in inner medullary collecting ducts. This 
phenomenon may be due to an increase in the passive 
permeability of capillary collecting ducts to sodium and/or 
to an alteration in inner medullary haemodynamics 
(Sonnenberg 1986). 
22 
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1.4.3 Other Effects of ANP: 
ANP induces a prompt and marked inhibition of renin 
secretion in intact dog (Burnett et al• 1984). A reduction 
in peripheral plasma renin activity has been observed in 
both conscious (Atlas 1986) and anaesthetized (Maack et al • 
1984) dogs and in man (Cody et al• 1986). It has also been 
shown that ANP inhibits aldosterone production by rat or 
bovine adrenal cortical cells in vitro (Atarashi et al • 
1984,• Kudo et al• 1984; Goodfriend et al• 1984) and lowers 
plasma aldosterone level in experimental animals (Volpe et 
al. 1985) and normal human subjects (Cody et al, 1986). 
Systemic administration of ANP has been shown to "have a 
potent inhibition on haemorrhage- or dehydration- induced 
vasopressin release in intact rats (Samson 1985)• Moreover, 
the effect of ANP on many target organs can be 
characterized as functional antagonism of the actions of 
hormonal agonists. This is particularly evident with regard 
to its actions on vascular smooth muscle, where ANP opposes 
vasoconstriction induced by catecholamines and other 
biogenic amines, angiotensin II, and vasopressin; on the 
adrenal cortex, where ANP inhibits aldosterone production 
stimulated by all known secretagogues. 
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1.5 Clinical Implications 
1.5.1 ANP and Heart Failure: 
Many workers {Bates et al. 1985; Tikkanen et al • 1985; 
Ogawa et al • 1986; Raine et al • 1986; Katoh et al • 1986) 
have demonstrated significant increase in plasma irANP 
concentrations in patients with congestive heart failure. 
The increase in plasma irANP levels is parallel to the 
severity of the congestive heart failure. Plasma irANP 
level falls in all patients as treatment improved their 
symptoms (Katoh et al• 1986). A close correlation has been 
found between the right atrial and pulmonary wedge pressure 
on the one hand and plasma irANP concentrations on the 
other (Raine et al. 1986; Ogawa et al. 1986). Such results 
are consistent with the observation that the plasma levels 
of cGMP, a marker of ANP activity, are significantly 
increased in patients with congestive heart failure (Ogawa 
et al. 1986). 
On the other hand, administration of ANP to patients 
with congestive heart failure has been studied (Crozier et 
al. 1986; Xu et al. 1986; Riegger et al• 1986). Generally, 
a good correlation is found between plasma irANP levels and 
mean right atrial and pulmonary wedge pressure. An increase 
in cardiac output is observed, with a decrease in mean 
systemic arterial, pulmonary, and right atrial pressure. In 
addition, ANP does not activate the renin-angiotensin-
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aldosterone system and vasopressin release. Therefore, it 
might find a place in treating heart failure. 
1.5.2 ANP and Hypertension: 
ANP is a vasorelaxant that also promotes natriuresis 
and diuresis, contracts blood volume, and inhibits the 
secretion of renin, aldosterone, and vasopressin. Such a 
pharmacodynamic profile would be very attractive in an 
antihypertensive drug, and studies of the cardiovascular 
actions of ANP in animal models and in humans have been the 
subject of many reports. 
In animal models, plasma ANP is similar in young 
spontaneously hypertensive rat (SHR) and Wistar Kyoto rat 
(WKY) , but as the rats age and SHR become hypertensive, 
plasma ANP increases several fold in SHR but not in WKY 
( � m a d a et al. 1985). Because ANP is in the nervous system 
and may function as a neuropeptide transmitter or 
modulator, it has been measured in the brain of SHR. In the 
hypothalamus and pons, ANP was higher in SHR than WKY at 8 
week of age and after but not at weaning (Imada et al. 
1985)• There is a consensus that ANP reduces blood pressure 
in bolus injections and in chronic infusions, and the 
effect on blood pressure is greater in SHR than WKY (Pang 
et al. 1985) . It is typical for a hypotensive agent to 
reduce blood pressure more in a hypertensive than in a 
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normotensive animal, but the reason for this is still 
obscure. 
In humans, the absence of any increase in plasma irANP 
concentrations in patients with mild essential hypertension 
(Larochelle et al. 1987a; Zachariah et al. 1987; Hedner et 
3.1. 1986) has been demonstrated. These groups also 
demonstrated that the plasma levels of cGMP, which is the 
marker of ANP activity, were not increased in patients with 
mild essential hypertension, as compared with normal 
subjects. On the other hand, groups of patients with severe 
essential hypertension, with diastolic pressure above 110 
itmiHg, and uncontrolled with antihypertensive medication 
have significantly elevated mean plasma irANP levels 
(Larochelle et al • 1987a)• Because ANP has the potential to 
reverse vasoconstriction and lower blood pressure, 
exogenous ANP has been administered to the hypertensive 
population. Initial reports demonstrated a reduction of 
blood pressure during ANP administration and an enhanced 
natriuretic response (Richards et al • 1985a). Therefore, 
ANP, as a support to the natural compensatory mechanism, 
may have therapeutic uses in some hypertensive disorders. 
1.5.3 ANP and Other Disorders: 
Patients with severe chronic renal failure show 
significant increase in plasma irANP levels, which decrease 
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significantly following haemodialysis (Larochelle et al. 
1987a)• The administration of ANP to a patient with severe 
treatment-resistant ascites due to terminal alcoholic 
cirrhosis resulted in a significant increase in urinary 
volume and sodium excretion, a marked decrease in plasma 
aldosterone concentration, and a fall in blood pressure 
(Fyhrquist et al. 1985). Insulin dependent diabetic 
patients have normal plasma irANP levels, but 4 out of 12 
with "cardiac autonomic neuropathy" had elevated levels 
(Kahn et al • 1986). Plasma irANP levels are lower in 
hypothyroid patients. These findings lead to some clinical 
implications beyond the cardiovascular system. 
1.5.4 Future Directions of Research: 
ANP has been administered to healthy volunteers and 
patients with different disorders. Meanwhile, several 
subjective and objective side effects with ANP 
administration at pharmacologic doses have been reported. 
Subjective symptoms consist of lightheadedness and nausea. 
Objective findings that coincide with the subjective 
symptoms include pallor or flushing, hypotension, 
bradycardia, and vomiting. Overall, this constellation of 
findings would be consistent with the response normally 
observed with stimulation of the vagal nervous system. 
Whether this is initiated by afferent vagal stimulation, or 
represents a direct central nervous system response, has 
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not been clarified. Although an enormous volume of data has 
accumulated regarding ANP, it is clear that much additional 
work is necessary. This work can be divided arbitrarily 
into two general categories: physiologic studies to 
determine the mechanisms governing ANP release and actions, 
and pharmacologic studies to determine the potential 
therapeutic implications of ANP. It would appear necessary 
that therapeutic consideration regarding ANP should include 
attempts to alter the baseline status of cardiovascular 
disorders such as congestive heart failure. In fact, 
synthetic analogues of ANP have been developed for 
potential use as therapeutic agents in the treatment of 
congestive heart failure and hypertension. 
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2.1 Introduction: 
The hypotensive effect of atrial extract was first 
elicited nine years ago by de Bold et al. in 1981. since 
then synthetic ANP has been administered not only to 
experimental animals but also to healthy volunteers and 
patients with some cadiovascular disorders including 
congestive heart failure and hypertension (see literature 
review). 
It seems clear that ANP can affect the heart»s action 
but it is not certain that this is due to a direct action 
on heart muscle. Synthetic rat atrial natriuretic peptide 
(rANP) has been found to decrease cardiac output in vivo 
(see literature review). Hirata et al. (1985) reported the 
specific binding sites for atrial natriuretic peptide in 
cultured mesenchymal nonmyocardial cells (NMCs) from rat 
atrial and ventricular tissues. He also reported that rANP 
significantly stimulated intracellular cGMP formation of 
cardiac NMCs in a dose-dependent manner (1.6x10"® M -
3.2x10"' M) . Moreover, binding sites of ANP have also been 
found in the endothelial lining of the four heart chambers 
of rat (Bianchi et al. 1985). Bergey and Kotler (1985) 
first described the effect of ANP on the cardiac tissue. 
They reported that atriopeptin 工 and 工工 produced a slight 
but significant reduction of contratile force of 
electrically paced guinea-pig's left atria at a 
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concentration of 3x10"® M. But these results are not 
supported by other workers. Synthetic rANP (IxlQ-^-SxlQ-'M) 
did not alter the contractile force of isolated papillary 
muscle of guinea-pig (Hiwatari et al • 1986) . Up to a 
concentration of 4.2x10"® M, atriopeptin 工工 did not alter 
the force of contraction in isolated rat cardiac tissues 
including left atria, left and right ventricular strips 
(Criscione et al• 1987). In isolated Langendorff-perfused 
guinea-pig heart, there was no direct cardiac effect of a-
hANP up to 64 nmol/g, as neither LVP nor dp/dt � were 
significantly changed by intra-aortic bolus injections of 
a-hANP. Although atriopeptin 工工 made a decrease in LVP, it 
has been ascribed to its concomitant coronary 
vasoconstriction (Otero et al. 1987). 
Meulemans et al• (1988) reported that atriopeptin III 
(10-9 M - 10-7 M) induced early relaxation and decreased peak 
tension of isometric and isotonic twitches of isolated 
papillary muscles of cat and rat. The actions of 
atriopeptin 工工工 was abolished by mechanically or chemically 
damaging the endocardial endothelial surface. Thus, the 
early relaxation of cardiac muscle induced by atrial 
natriuretic peptide may be mediated through the receptors 
on the endocardial endothelium. As discussed previously, 
some workers have found ANP to have little effect on the 
heart. The loss of integrity of endocardial endothelium 
may be the explanation of some of these results; it has 
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been claimed that ANP acts on the heart via endothelial 
receptors. The aim of present work was to reinvestigate 
this problem by studying the effect of ANP on heart muscle 
using perfused guinea-pig and rat left atrium preparations. 
This preparation has the advantage that it allows the 
atrial muscle to be assessed by the pressure which can 
generate under strictly controlled physiological conditions 
at near optimum end diastolic pressure conditions. There 
are other advantages using this preparation, with this 
preparation the integrity of the endocardial endothelium 
can be kept and ANP can be delivered into the atrial 
cavity. On the other hand, interference by coronary flow 
which occurs in isolated Langendorff-perfused heart‘can be 
avoided. Furthermore, it is more physiological to assess 
the contractile power of heart muscle in its natural 
configuration than in muscle strip preparations. 
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2.2 Methods: 
Fig.2-1 shows the atrial preparation and the 
experimental set up used in these experiments. The atrial 
preparation was mounted in an organ bath perfused at 
constant flow with suitable fluid and stimulated with an 
electrical stimulator while intraatrial pressure was 
measured with a pressure transducer. 
2.2.1 Preparation: 
The atrium was prepared with a slight modification of 
a published technique (Baumann and Reichel 1974) • Male 
guinea-pigs (weighing 500g to 700g) were killed by a blow 
on the head. After thoracotomy two of the pulmonary veins 
were cannulated. Cannula I was inserted into the left 
atrial cavity. This cannula had two channels. One of which 
was connected to a peristaltic pump (Fig.2-1), while 
another connected to a pressure transducer. Cannula 11 
served as outflow for the perfusion fluid from the left 
atrium. From the instant of killing to the beginning of 
perfusion, a time of 10-20 minutes was needed. The perfused 
left atrium was separated from the right atrium and from 
the right and left ventricles by ligatures. Then the two 
ventricles were cut off. After ligation of all non-
cannulated vessels, the perfused atrium was transferred 
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2.2.2 Bathing and Perfusion Fluid: 
Krebs Henseleit—solution of the following composition 
(in mmol/l) : Na+: 142.0; r � 5.9; Mg++: 1.2; Ca++: 2.54; CI": 
150.58; H2PO厂：1.2; SO4-": 1.2; Glucose: 11, buffered by HCl 
to pH 7.4, with thermostat-controlled temperature (37 
was used. The fluids perfusing both the atria and the organ 
bath were saturated with oxygen using bubbled gas with 95% 
O2 and 5% CO^. The bathing fluid (100 ml) was changed 
continuously at a constant rate of 2•0 ml/min. The flow of 
the perfusion fluid could be controlled by adjustment of 
the peristaltic pump. In most experiments this flow was 
maintained at a constant rate of 1.0 to 1.5 ml/min. 
2.2.3 Stimulation: 
The atrium was driven continuously by electrical 
stimuli of twice threshold intensity and of 1 msec duration 
and 270 stimuli/min. 
2.2.4 Pressure Recording System: 
The second side arm of cannula 工（Fig. 2-1) was 
connected directly by a rigid and short tube (diameter 1 
mm) to a Statham pressure transducer(P 23 ID) • Signals were 
recorded by a chart recorder and a cathode-ray oscilloscope 
after amplification. 
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2.2.5 Mechanical Properties and Reactions of the 
Preparation: 
Diastolic pressure could be adjusted by the adjustment 
of the peristaltic pump. It was maintained in a range of 
10±2 cm H2O, within which a change in atrial filling had no 
detectable effect on pulse pressure (range of the flat 
maximum of the Frank-Starling curve)• At the heart rate 
u s e d , � h e volume changes during contraction and relaxation 
were negligible, so that the contractions were almost 
isovolimetric. 
2.2.6 Experimental Procedure: 
Each individual preparation was stimulated throughout 
the experiment at a constant rate of 270 stimuli/min. After 
20 minutes of equilibration, the response of left atrium 
was checked by high and low concentrations of calcium Krebs 
solution. Then ANP was perfused into the atrium with 
concentrations from Ixicr" M to 1x10"' M . After checking the 
response again, Krebs solution was perfused into the atrium 
with the same protocol as a control perfusion instead of 
the ANP perfusion. Before the end of the experiment, the 
response of the atrium was checked by high and low calcium 
Krebs solution again. A total of six experiments were 
carried out, in which the order of ANP and vehicle 
treatments was alternated. The perfusion period was 5 min 
in every treatment. 
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2.2.7 Parameters measure: 
l.The atrial end-diastolic pressure 
2-The atrial peak pressure 
3.Pulse pressure which the atrium developed actively 
(difference between 2 and 1) 
2.2.8 ANP: 
Atrial natriuretic peptide (rat sequence with 28 
amino-acids) was from Sigma Chemical Company ( molecular 
Wt.3064 ). 
2.2.9 statistics: 
For statistical evaluation paired t test for 
correlated samples was used. 
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2.3 Results: 
Fig.2—2 shows the effect of intravenous injections of 
ANP on blood pressure in a guinea pig anaesthetized with 
urethane. ANP had little effect on arterial pressure in 
doses of O.OOlMg/kg and 0. l/xg/kg but it caused a profound 
fall in systolic, diastolic and mean pressure when 10/xg/kg 
was injected. These doses were calculated to produce 
approximate blood concentrations of ANP of lxlcr"M, IxlO'^M 
and IxlO-'M respectively. 
Fig.2-3 shows an original record of a typical 
experiment to study the effect of ANP on atrial 
contractility. Shown in the upper record, at the beginning 
of the experiment the end-diastolic pressure was 9 cm H^O 
and the pulse pressure was 10.5 cm H^O. When the calcium 
concentration in the perfusate was doubled, pulse pressure 
increased to almost 13 cm H,0, though the end - d i a s t o l i c 
pressure fell slightly. When the calcium level in the 
perfusate was halved the reverse occurred. Pulse pressure 
fell to about 8 cm H,0 though end-diastolic pressure rose 
slightly. ANP was then given in increasing doses to produce 
drug concentrations of icr", lO"® and lO'^M respectively over 
successive 5 min periods. There was no detectable change in 
the end-diastolic or pulse pressure with any of the 
concentrations. The treatments with high and low calcium 
perfusate was then repeated and the effects were similar to 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Section 2: Effect of ANP on Left Atrium 
similar experimental run but in this case the ANP infusions 
were replaced with vehicle infusions. The responses of the 
vehicle infusions were similar to those of the ANP 
infusions i.e. they had no effect on diastolic or pulse 
pressure in the atrium. 
Six sets of observations of the sort shown in Fig.2-3 
were carried out. In three of these the ANP infusions were 
given first and in the other three, the vehicle infusions 
were given first. 
Fig. 2—4 shows the mean value obtained in the 51:h 
minute of each 5 minute period of the experiment, the 
vertical bars representing 1 standard error of mean (SEM)• 
The upper panel shows the means of the ANP runs. Whereas 
increasing and decreasing the calcium concentration in the 
perfusate at the beginning and end of the runs increased 
and decreased the pulse pressure respectively, perfusing 
the atria with ANP in concentrations of lO"", icr® and icr? 
M had very little effect other than a slight decline in the 
mean pulse pressure. The lower panel shows the means of the 
runs where vehicle infusions were given. The results were 
very similar to those of the ANP runs. Again raising and 
lowering the calcium concentration increased and decreased 
the pulse pressure respectively and there was a slight and 
gradual decline in the pulse pressure during the period of 
the vehicle infusions (as in the ANP runs)• 
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1 5 1 A: ANP runs • Vehicle 
EZ I ANP 
i.i i i iL 
HCa LCq HCq LCa 
15 1 B: Contro l runs 
� High Calcium ( 5 m M ) 
令 CSJLow Calcium ( 1 . 2 5 m M ) 卜 i l i i 
HCa LCa HCa LCa 
F i g . ” The mean value of pulse pressures obtained in the 5th 
j^inute of each 5 minute period of the experiment, the vertical 
bars representing 1 standard error of mean (SEM). The upper 
panel shows ANP runs. The lower panel shows the means of the 
runs where vehicle infusions were given. HCa:high 
concentration of calcium (5mM); LCa:low concentration of 
？ 二 ， • 二 ; ’ 二V)。-9’ 10-7: ANP in concentrations of 
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Fig.2-5 summarizes the changes in pulse pressure seen 
with exposure to the different infusions expressed in 
absolute terms. Each change was calculated as the 
difference between the experimental value during exposure 
and the mean of the value during the periods which 
immediately preceded and followed the exposure. The closed 
triangles show the change during the ANP runs. High calcium 
increased the pulse pressure by about 1 cm H2O. The change 
was significant statistically (p<0.05). Lowering the 
calcium decreased the pulse pressure by about 2.5 cm H2O. 
The change was highly significant (p<0.01) . ANP at all 
concentrations caused virtually no change in the pulse 
pressure nor did it affect the subsequent responses to 
changes in the calcium concentrations. The open triangles 
show the data from the control runs presented in exactly 
the same way. It can be seen that they are virtually 
indistinguishable. 
The same experiments have also been done with two rat 
atria. The response of the rat atrial preparations was 
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2.4 Discussion: 
In the present experiments we used isolated perfused 
atrial preparation with intact endocardial endothelium and 
delivered ANP into the cavity of left atrium. Besides 
intact endocardial endothelium, there were some other 
advantages of this preparation over others. Firstly , we 
measured intraatrial pressure as an index of myocardial 
contractility. This is a more physiological index than 
measuring tension development using muscle strip 
preparations. Secondly, we checked the response of the 
atria with different concentrations of calcium solution 
before and after the experimental runs to demonstrate that 
the preparation was capable of responding reliably to 
inotropic agents. Furthermore, we had control experiments 
which alternated with the ANP experiments to test the 
effect of the vehicle alone on the preparation. However, 
our study found that the effect of ANP perfusions was no 
different from the effect of the vehicle alone on the 
preparation so it was concluded that rANP has no effect on 
isolated perfused atria. 
our results are different to those of Bergey and 
Kotler (1985). They reported that atriopeptin I and II 
produced a slight but significant reduction of contractile 
force in electrically paced guinea-pig's left atria at the 
concentration of 3x10- M compared with predrug value, in 
their experiments, there were not any time controls, so the 
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Slight reduction of contractile force may have been due to 
the natural deterioration in the contractility of the 
isolated preparations. 
Our results are also different to that of Meuleinans et 
al. (1988) . He reported that atriopeptin 工工工(lo-^  m - icr? 
M) induced early relaxation and decreased peak twitch of 
isometric and isotonic twitches of isolated papillary 
muscles of cat and rat. The action of atriopeptin III was 
abolished by mechanically or chemically damaging the 
endocardial endothelial surface. These results suggest that 
the early relaxation of cardiac muscle induced by atrial 
natriuretic peptide may be mediated through the receptors 
on the endocardial endothelium. However, we used isolated 
perfused atrial preparation with intact endocardial 
endothelium and delivered ANP into the cavity of left 
atrium. We found that there was no effect of rANP on the 
isolated perfused atria. There are two possible 
explanations for this discrepancy. Firstly, there may be a 
difference in the properties of papillary muscle and atrial 
muscle, secondly, it may be due to the form of ANP used. 
Although rat atrial natriuretic peptide (rANP) (28 amino 
acids) is the major circulating form (Schwartz et al • 
1985), it may not be the form of major biological 
importance. In the case of angiotensin, angiotensin I is 
the predominant form in the venous circulation, although 
angiotensin II is the major biologically active form. A 
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previous study showed that low molecular weight fragments, 
isolated from rat atrial extracts, contain the amino acid 
sequences for Atriopeptin 工 （ A P 工 ） （ 2 1 amino acids) and 
Atriopeptin 工 工 （ A P 工 工 ） （ 2 3 amino acids) (Wakitani et al. 
1985)• Other studies have shown that intracoronary AP 工工 
injections elicited a marked coronary constriction in rats, 
guinea pigs and anaesthetized dogs (Wangler et al• 1985). 
Moreover, it has also been reported that atriopeptin 工工工 
(AP 工工工），a 24-amino acid atrial peptide, is a potent 
vasodilator and natriuretic/diuretic agent in normal rats 
(Cole et al. 1985). These findings support the second 
possibility for the discrepancy between our results and 
those of Meulemans et al. (1988). Therefore, the effect of 
other active fragments of ANP on our atrial preparation 
should be further investigated. On the other hand, ANP may 
decrease the arterial blood pressure through the mechanisms 
other than the direct negative inotropic effect on cardiac 
muscle. 
In the present experiments ANP lowered the blood 
pressure. It had no effect on atrial muscle even though 
doubling and halving the calcium concentration had. It is 
concluded that the depressor effect of ANP in the guinea-
pig is unlikely to be mediated through an action on the 
heart. It should be remembered that the above conclusion is 
only based on experiments with acute administration of ANP. 
The long term effect of ANP on heart muscle still needs 
further clarification. 
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3.1 Introduction: 
The first indication that atrial natriuretic peptide 
had an effect on vascular smooth muscle came from in vitro 
experiments with vascular strips (Currie et al • 1983)• Both 
in rabbit facial vein and rabbit aorta, ANP was found to 
cause a prompt relaxation of pre-induced tone (Winquist et 
al• 1984). Thus it quickly became accepted that ANP was a 
powerful vasodilator. 
Nevertheless, this was not supported by in vivo 
experiments. Intravenous infusion of increasing doses of 
atriopeptin 工 工 （ A P 工工） to conscious unrestrained rats 
caused a dose-dependent fall in mean arterial pressure. 
Blood flow in the renal, mesenteric, and hindguarter 
vascular beds was markedly decreased during the infusion, 
and regional vascular resistance was significantly 
increased (Lappe et al • 1985). Hofbauer et al. (1986) 
reported a similar result. Infusion of atriopeptin 工工 
intravenously produced a fall in blood pressure and a rise 
in heart rate, accompanied by a significant decrease in 
renal and mesenteric blood flow. These findings suggest 
that the hypotensive effect of atriopeptin 工工 in conscious 
rats is not mediated by systemic vasodilatation. Chemical 
sympathectomy prevented the fall in renal blood flow (RBF) 
and significantly abolished the regional vasoconstrictor 
responses to AP 11 infusion in rats (Lappe et al • 1985). 
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These data further indicate that in conscious rat the 
regional vasoconstrictor responses to AP 工工 infusion appear 
to be mediated by an increase in sympathetic tone rather 
than through direct vascular actions of AP II. 
However, low dose (5 micrograms/kg) injection of 
atriopeptins to conscious dogs exerted no significant 
effect on systemic arterial pressure, heart rate, coronary, 
mesenteric, or iliac blood flows. But it increased renal 
blood flow and reduced renal vascular resistance (Hintze et 
al • 1985) . This indicates that in the conscious dog, 
atriopeptin 工工 and 工工工 are selective renal vasodilators 
that do not exhibit systemic hemodynamic effects. This 
hypothesis has been supported by some in vitro studies. 
Aalkjaer et al. (1985) have investigated the effect of 
synthetic ANP on induced tone in rat isolated renal arcuate 
arteries (lumen diameter 250 microns), and compared this 
with the effects of synthetic ANP on resistance vessels of 
similar size taken from the mesenteric, femoral, cerebral 
and coronary vasculature. Synthetic ANP was found to cause 
relaxation of the renal vessels when these were 
sub-maximally activated with high potassium and 
noradrenaline but had no effect on the responses of the 
other vessels to these agonists. Moreover, Osol et al. 
(1986) observed the effects of synthetic atrial natriuretic 
peptide and atriopeptin 工工工 on induced tone in isolated 
resistance-sized mesenteric and cerebral arteries from the 
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rat. Atrial natriuretic peptide or atriopeptin 工工工 did not 
alter the contractile responses of cerebral vessels to 
serotonin or prostaglandin F2 alpha. Mesenteric arteries, 
which do not possess an intrinsic myogenic tone, were 
precontracted with potassium (30 mM), norepinephrine 
(lO-'M), or prostaglandin F2 alpha (I.IXICT^M) and exposed 
to the synthetic natriuretic peptides. It also had no 
effect. Furthermore, atriopeptin 工工工 relaxed isolated aorta 
and intrarenal microarteries but not coronary and 
mesenteric microarteries of normotensive rats (de Mey et 
al. 1987). These results indicate that ANP has a specific 
vasodilator effect on the renal vasculature. 
Nevertheless, ANP also lowers the blood pressure and 
causes haemoconcentration in anephric animals (Huxley et 
al. 1987; Trippodo and Barbee 1987). Moreover, Caramelo et 
al. (1986) observed the effect of the intravenous injection 
of synthetic atrial natriuretic peptide on systemic 
haemodynamics and blood flow to several organs in conscious 
rats. Renal blood flow increased by 37.7% and small 
intestine and portal blood flow increased by 39% and by 28% 
respectively. These data suggest that atrial natriuretic 
peptide is not only specific for renal but also acts in 
mesenteric territories. The presence of a specific 
high-affinity vascular receptor for atrial natriuretic 
peptide in mesenteric artery preparation (Lyall et al. 
1987) reinforces this postulate. 
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The first indication that atrial natriuretic peptide 
had a vasodilator effect on resistance-size mesenteric 
artery came from in vitro experiments with vascular strips 
(Cauvin et al• 1987). Activation of rat's vessels by icr、 
noradrenaline (both phasic and tonic contraction) was 
inhibited quite effectively and potently by AP III. The 
concentration of AP III that inhibited contraction by 5 0 % 
for noradrenaline-induced phasic tension was 3 . 1 士 1 . 3 nM. 
These studies contrast with earlier reports that similar 
peptides inhibited tension only in rat renal resistance 
vessels and not in resistance vessels from other vascular 
beds. The reasons for this discrepancy is not at all clear. 
Therefore, we investigated the effect of ANP on rat's 
mesenteric artery using an in situ preparation, with this 
preparation, ANP can be administered to the artery locally 
so that it will not affect the systemic arterial blood 
pressure and will not activate the reflex mechanisms which 
occur in the in vivo experiments. On the other hand, the 
artery can be observed under reasonably physiological 
condition. This is an improvement over some of the in vitro 
studies. 
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3.2 Methods: 
3.2.1 Animals: 
Eight male Sprague-Dawley rats (weighing 350-400g) 
supplied by the Animal House of The Chinese University of 
Hong Kong were used for the present study. The rats were 
anaesthetized with urethane (1.5g/kg i.m.). After 
anaesthesia, the trachea, left carotid artery and left 
jugular vein were cannulated. The rats were allowed to 
breathe spontaneously. The arterial pressure was monitored 
continuously through the carotid artery catheter. The 
jugular vein catheter served for supplemental anaesthesia 
if necessary. 
3.2.2 Mesenteric Artery Preparation: 
After cannulation, a midline abdominal incision was 
made (Fig.3-1). Then a segment of small intestine was 
pulled out gently and the mesenteric vessels were exposed 
over a specially designed perspex viewing platform and 
which was frequently suffused with bicarbonate-buffered 
Ringer‘s solution comprising (in mM) NaCl 131.9, KCl 4 . 7 , 
CaCls 2 . 0 , MgS0"7H20 1.2, and NaUCO, 20. Ascorbic acid 
(0.5inM) was added as an antioxidant. The solution was 
saturated with 5% CO^ and 95% with a dissecting 
microscope, a medium size (resting diameter from 250 to 325 
micrometer) mesenteric artery was separated from its 
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along the artery was torn away carefully. After dissection, 
the artery was superfused continuously with the Ringer's 
solution by a temperature controlled suffusing system. 
Then, the artery was transilluminated and observed with a 
video microscope system described below. 
3.2.3 Video Microscope System: 
The artery preparation was transilluminated by a 150-
watt projection lamp through a reflecting mirror (Fig.3-2) 
and was observed with an American Optical custom industrial 
microscope (model 3003) fitted with an Olympus 404732 
M5/0.1 objective lens. The resulting optical images from 
the mesenteric artery were coupled to a closed-circuit 
video camera (RAC model TC1005) through a microscope 
eyepiece (Olympus FK2.5x) and observed on a video monitor 
(National model WV-5350, 9-inch)• The videocamera consisted 
of a 1-inch Ultricon tube (RCA model 4532/U) which was 
sensitive to low light intensities. Then the optical image 
was sent to a dynamic video diameter analyzer. Thereby the 
artery could be observed on a video monitor and the artery 
diameter could be recorded by a strip-chart recorder. The 
overall optical and video linear magnification of the 
artery, as observed on the video monitor, was 80x. 
3.2.4 Automatic Video Diameter Analyzer: 
In the present study, quantitative observations were 
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measured with an automatic video analyzer. As a 
prerequisite for the proper operation of this automatic 
video diameter analyzer, the image of an artery projected 
on the video camera, and observed on the video monitor, 
must be rotated to align horizontally and parallel to each 
of the video raster lines. This was achieved by interposing 
a k-mirror between the microscope eyepiece and the video 
camera. The k-mirror was constructed as described by 
Wayland and Frasher (1973)• 
The video analyzer was interposed between the video 
camera and the video monitor, and it generated a 
positionable rectangular window (of fixed width, but 
adjustable height) which was observed on the video monitor 
together with the image of the artery. This window was 
called the main detecting window, and its position on the 
video monitor was controlled by a joystick mechanism. 
When measuring the diameter of an artery, the main 
detecting window was superimposed perpendicularly to the 
axis of the horizontally—aligned vessel (Fig.3-3)• Usually, 
there was good optical contrast between the dark image of 
an artery and its contents, and the lighter image of the 
surrounding tissue. Within the main detecting window, the 
analyzer automatically sampled the video signal of the 
images of both the artery and its surrounding tissue, and 
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raster lines. At the same time, the analyzer also counted, 
within the main detecting window, the number of those video 
raster lines occupied by the artery and its contents (the 
dark image), and it ignored those raster line corresponding 
to the tissue (the light image)• In this manner, once the 
analyzer had been calibrated with a stage micrometer scale 
(100 divisions; 10 Mm/division), the analog voltage output 
of the main detecting window, reflecting the number of 
raster lines occupied by the artery and its contents, would 
provide an absolute measurement of the diameter of that 
artery. For example, when an artery was dilated, the number 
of raster lines occupied by that dilated vessel increased 
correspondingly, and the voltage output from the main 
detecting window was also increased. The voltage output of 
the main detecting window was either displayed on a digital 
panel meter or fed into a strip-chart recorder. Thus the 
diameter of an artery could be automatically, 
instantaneously and continuously observed and measured. 
Sometimes the optical contrast between the artery and 
its surrounding tissue would change during an experiment 
due to movement of the artery preparation, fluctuation of 
the light source intensity, or optical interference caused 
by particles in the suffusing solution. Therefore, the 
following technique was employed to ensure that the 
automatic detection of artery diameter was accurate 
throughout the experiment. 
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An auxiliary rectangular window was generated and 
positioned alongside the main detecting window. This 
auxiliary window had a fixed width, but its height was 
controlled from the main detecting window via an electronic 
servo mechanism. Thus while the main detecting window was 
instantaneously measuring the diameter of an artery, it was 
also controlling the auxiliary window such that the height 
of the latter was identical to the diameter of the artery 
(Fig.3-3B) . When the setting of the video threshold level 
control of the main detecting window was not optimal the 
detecting window would over- or underestimate the diameters 
of the artery. When such a discrepancy arose, the 
experimenter would adjust the video threshold level control 
of the main detecting window until the height of the 
auxiliary window exactly covered the diameter of the 
artery. Therefore, the experimenter was, in a sense, a 
component of the automatic video diameter analyzer system, 
as he had to check constantly that the height of the 
auxiliary window was the same as the artery diameter. 
3.2.5 Suffusing System: 
Ringer's solution was delivered to the artery by a 
peristaltic pump (Watson-Marlow, model 502) via a glass 
tube (i.d. 3mm, 300im long) wrapped in a heating coil (Fig. 
3-4) • A built-in thermister at the tip of the glass tube 
detected the temperature of the suffusing solution and fed 
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Effect of ANP on mesenteric SLTtery 
passing through the heating coil; thus the suffusing 
solution was maintained at 37。C. 
The peptide solution was delivered by a syringe 
infusion pump (Harvard Apparatus, model 975A) via a length 
of polyethylene tubing (size PP50) inserted inside the 
glass tube and terminating about 20mm from the tip of the 
tube. Since the end of the polyethylene tubing was set back 
from the tip of the glass tube, there was sufficient space 
for the peptide to mix with the suffusing solution before 
the equilibrated solution was topically applied to the 
artery preparation. 
When the peristaltic pump delivered the suffusing 
solution through the glass tube at a rate of 1.44 ml/min 
and the syringe infusion pump delivered the peptide 
solution through the polyethylene tubing at 0.16 ml/min, 
the overall rate of suffusion was 1.6 ml/min. The 
difference in the two infusion rates produced a 10-fold 
dilution of the peptide solution, and the dead space in the 
suffusing system produced a delay before the diluted and 
mixed peptide solution reached the ±n situ artery 
preparation. 
3.2.6 Protocol: 
After dissection, the preparations were moved to the 
video microscope system and the diameters of the arteries 
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were measured. Then the arteries were suffused with 
Ringer，s solution by the suffusing system continuously. 
After equilibration (15-20 min), the arteries were 
preconstricted by noradrenaline (10"® M about half of 
maximum constriction)• A stable base line was available in 
5-10 min. Then normal Ringer‘s solution, ANP(10"^M), second 
normal Ringer‘s solution and sodium nitroprusside (lO""^) 
were superfused to the arteries in order by the syringe 
infusion pump. Each treatment period was 5 min. 
3.2.7 Statistics: 
Every treatment was compared with its pretreated value 
by paired t test. It was considered to be significant if 
the p value was less than 0.05. 
3.2.8 Chemicals: 
Urethane was from Sigma Chemical Company (No: U-2500)• 
Arterenol (noradrenaline hydrochloride) was from Sigma 
Chemical Company (No: A-7381). Sodium nitroprusside was 
from Aldrich (22,871-0). 
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3.3 Results: 
Fig.3-5 shows an original record of a typical 
experiment to study the effect of ANP on mesenteric artery. 
Before noradrenaline preconstriction, the artery diameter 
was about 250 Then noradrenaline (10"^) preconstricted 
the artery to 150 i^ti. After 5-10 min, a stable base line 
was available and normal Ringer's solution was superfused 
onto the artery. It made little change in the artery 
diameter. Then ANP (10"'M) was superfused onto the artery 
and it caused a slight increase in the artery diameter. 
After the ANP treatment, the response of the preparation 
was tested by another superfusion of normal Ringer's 
solution. It also made little change on the artery 
diameter. At the end of the experiment, sodium 
nitroprusside (lO""^) was superfused onto the artery and it 
caused a bigger and earlier increase in the artery 
diameter. Eight experiments of this sort were carried out. 
Fig. 3-6 shows the mean of the eight experiments and 
the error bars represent 1 SEM. Before noradrenaline 
preconstriction, the mean artery diameter was 278±8 ^m. 
Noradrenaline induced a constriction of the artery to 
157±12 Mm. Then superfusion of normal Ringer's solution 
caused a small increase in artery diameter to 161±13 /xm but 
this was not significant statistically. Before ANP 
treatment, the mean artery diameter was 158±13 /zm. 
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Superfusion of ANP caused a slight (176±13 /xin) but 
significant (p<0.05) increase in the artery diameter. The 
second treatment of normal Ringer‘s solution caused little 
change. At the end of the experiments, sodium nitroprusside 
caused a dramatic increase in the artery diameter. In 
conclusion, the results showed that ANP caused a slight but 
significant relaxation (15%) of the rat's mesenteric 
artery. With sodium nitroprusside the relaxation was almost 
100%. 
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3.4 Discussion: 
In our experiment, ANP in high pharmacological dose 
(lO'^M) only caused a slight relaxation of the mesenteric 
artery. The vasodilator effect is so weak that it could be 
easily overcome by the strong reflex mechanisms in vivo. On 
the other hand, our results are different to that of the in 
vitro study made by Cauvin et al. (1987). They reported a 
vasodilator effect of atriopeptin 工 工 工 （ A P 工工 I ) on isolated 
mesenteric resistance artery from rat. The concentration of 
AP 工工工 that inhibited contraction by 50% for noradrenaline— 
induced phasic tension was 3.1 士 1.3 nM. To explain this 
discrepancy, there are two possibilities. Firstly,.it may 
be due to the different sizes of the arteries used and the 
distribution of the receptor for ANP. In our experiment, 
the internal diameter of the arteries was about 270 /xm 
while it was about 100 jum in Cauvin * s study. Secondly, it 
may have been due to the form of ANP used. In our 
experiment, rat ANP (Ser 99 - Tyr 126), the main 
circulating form in rat, was used while AP 工工工（ S e r 103 一 
Tyr 126) was used in his study. Therefore, the effect of 
other forms of ANP on smaller mesenteric arteries should be 
observed in further investigation. 
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Intravenous injection of Atrial Natriuretic Peptide in 
pharmacological dose induces a dramatic fall in the 
arterial pressure. The mechanism of this effect is still 
not fully understood. The acute fall in arterial pressure 
may be attributed to many mechanisms but we have only 
looked at two possibilities - a possible fall in left 
atrial contractility and a possible decrease in mesenteric 
artery tone. In left atrium preparations with intact 
endocardium, ANP had little effect on heart muscle 
contractility. This result is consistent with previous 
studies (see section 2 introduction), though Meulemans et 
al. (1988) reported that atriopeptin 工工工 （ l O - S - i c r ' M ) 
inhibited cardiac contractility in isolated papillary 
muscles of rat and cat. Although other forms of ANP, 
especially atriopeptin 工 工 工 ， h a v e not been tested on our 
preparation, it is unlikely that ANP lowers the arterial 
pressure through a depression of heart muscle 
contractility. In the In situ medium size mesenteric artery 
preparation, ANP only had a slight vasodilator effect which 
could not fully explain the dramatic fall in the arterial 
pressure. 
In addition to the negative results of the In vitro 
studies, in in vivo experiments, administration of ANP 
decreases the cardiac filling pressure (see section 1 pi9) • 
If ANP depressed cardiac contractility, one would expect 
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cardiac filling pressure to rise. ANP also does not alter 
cardiac rhythm through a direct effect on the sinoatrial 
node (Natsume et ai• 1986). Thus, it is more likely 七 h a t 
the primary means by which ANP diminishes cardiac output 
and arterial pressure is through its action on 七 h e 
peripheral circulation to decrease venous return. 
It has been proposed that ANP may have a selective 
relaxant effect on venous smooth muscle, thereby decreasing 
central venous pressure. But it is not consistent with in 
vitro studies on large veins showing no effect of ANP 
(Faison et al. 1985). Moreover, Trippodo et al• (1986) 
Observed in anaesthetized rats that infusion of ANP reduced 
rather than increased circulatory capacitance and increased 
venous resistance in association with a reduction in atrial 
pressure and cardiac output. This was attributed to active 
venoconstriction. Although it is co職only assumed that 
venous constriction and reduced compliance will increase 
venous return and cardiac output, circulatory models and 
experimental data indicate that an increase in venous 
resistance, particularly in the peripheral venous 
compartment, can reduce venous return and cardiac output 
(Rothe 1983). 
The mechanism for the active venoconstriction is 
unknown but could involve baroreflexes and/or release of 
circulating vasoconstriction hormones. There is both in 
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vitro and In vivo evidence that adrenergic control of 
skeletal muscle venules and many veins (Langer et al • 1984; 
Tornebrandt et al. 1985) utilizes predominantly 
postjunctional ag-adrenoceptors. In contrast, recent studies 
(Faber 1988; Langer et al • 1984) suggest that adrenergic 
control of the arterial and arteriolar circulation may rely 
predominantly on ai~adrenoceptors. On the other hand, a 
recent study (Faber 1988) indicates that ANP exhibits a 
high potency and selectivity for reversal of 
adrenoceptor-mediated constriction of large arterioles and 
venules. Constriction produced by ag-adrenoceptor occupation 
or by nonadrenergic "intrinsic" mechanisms appears to be 
insensitive to ANP. These findings lead to the following 
hypothesis. Acute administration of ANP inhibits basal a!-
mediated tone of large arterioles leading to a momentary 
reduction in peripheral resistance and an increase in 
capillary pressure and flow. Overall venous adrenergic 
tone, which relies predominantly on ttg-adrenceptors, would 
be little affected. The increase in capillary pressure, 
together with a possible effect of ANP to increase 
capillary conductivity (Meyer et al• 1987) would increase 
capillary filtration and explain the persistent though 
attenuated reduction in plasma volume in anephric rats 
(Huxley et al. 1987). Arterial pressure would momentarily 
decrease due to a reduction in cardiac output (secondary to 
a decrease in plasma volume and venous return) and the 
decrease in peripheral resistance. The hypotension would 
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activate arterial baroreflexes and increase sympathetic 
outflow. Baroreflex activation would constrict large 
arterioles by increasing noradrenaline activity at a^-
receptors and would counteract inhibition by ANP; 
peripheral resistance would be maintained near normal. 
However, the concomitant increase in sympathetic activity 
to venules and veins would produce constriction via 
predominantly as-adrenoceptors that would be unaffected by 
ANP. This could explain the increase in venous resistance 
observed by Trippodo et al • (1986). Consistent with this 
sympathetic venoconstriction hypothesis, the ANP-induced 
decrease in cardiac output was almost eliminated in rats 
subjected to chemical sympathectomy (Sasaki et al. 1986). 
Decreased venous return and increased capillary pressure 
and filtration, favouring reduce plasma volume. These 
mechanisms would reduce cardiac output further. If ANP does 
cause a shift of fluid to the tissue it should result in an 
increase in lymph formation. To test this hypothesis, the 
effect of ANP on lymph formation will be observed in 
further investigation. 
At this time, it is necessary to emphasize the fact 
七 h a t all these experiments have been performed under acute 
adminstration of ANP. Low dose (below 6ng/kg/min) infusions 
of ANP make not only a modest and consistent natriuresis 
but also a significant fall in arterial pressure (Richards 
et al. 1988 )• Both systolic and mean arterial pressure 
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were significantly reduced by these small ANP infusions in 
normal subjects. By means of longer infusions at a slightly 
higher rate in hypertensive subjects, Janssen et al• found 
that plasma ANP increment of approximately 16 pmol/l 
maintained for 5 days induced substantial and prompt 
natriuresis and a slower but sustained lowering of blood 
pressure. Thus, small and sustained increment of ANP will 
be likely to be of therapeutic importance. But synthetic 
ANP is very expensive and it can not be used orally. There 
is a limitation in its practical uses. Fortunately, plasma 
ANP levels appear to show little fluctuation despite the 
hormone‘s high clearance and disappearance rate from plasma 
under normal circumstances (Espiner and Nicholls- 1987). 
This stability suggests a continuing high production rate. 
Therefore, the successful development of agents able to 
inhibit neutral endopeptidase activity, thereby impeding 
ANP degradation and promoting and sustaining its action in 
association with small increments in plasma ANP levels 
(Sybertz et al• 1988) point to the first practical 
application of these findings in the treatment of 
hypertension and related cardiovascular disorders. However, 
the long term effects of small and sustained increments of 
plasma ANP level is still not obvious. Therefore, further 
investigations are needed. 
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